Sfoglia per AUTORE
DONINI M
Collezione AOU San Luigi di Orbassano

  

Items : 12

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.

2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli

Buttigliero C; Zucali P; Tucci M; Verri E; Mosca A; Procopio G; Mucciarini C; Fratino L; Masini C; Massari F; Fornarini G; Ermacora P; Donini M; Buti S; Ceresoli GL; Berruti A; Caffo O; Bortolus R; Baldessari C; Zagonel V;

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2019 Apr;15(10):1115-1123. doi: 10.2217/fon-2018-0715. Epub 2019 Mar 19.

2019
AOU San Luigi di Orbassano

Veccia A; Rossetti S; Mucciarini C; Conteduca V; Basso U; Chiuri VE; Guida A; Calvani N; Buttigliero C; Donini M; Ferraù F; Morelli F; Biasco E; Facchini G; Caffo O; Maines F; Kinspergher S; De Giorgi U;

Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study in Journal of Clinical Oncology

2017
AOU San Luigi di Orbassano

Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Rossetti S; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini PF; Damiani A; Procopio G; De Lisi D; Ruatta F; Scagliarini S; Donini M; Sperduti I; Basso U;

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration resistant prostate cancer (MCRPC) patients receiving a new agent (NA)-based third-line treatment. Final results from a multicenter Italian study in Anticancer Research

2017
AOU San Luigi di Orbassano

Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Facchini G; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini P; Damiani A; Procopio G; De Lisi D; Ortega C; Scagliarini S; Donini M; Sperduti I; Basso U;

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)-based third-line treatment: Final results from a multicenter Italian study in Journal of Clinical Oncology

2017
AOU San Luigi di Orbassano

Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Rossetti S; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini P; Damiani A; Procopio G; De Lisi D; Ortega C; Scagliarini S; Donini M; Sperduti I; Basso U;

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.

2016
AOU San Luigi di Orbassano
ASL Torino 5

Santini D; Messina C; Perin A; Lodde M; Fratino L; Berruti A; Mucciarini C; Nicodemo M; Bonetti A; Alesini D; Zucali PA; Vicario G; Massari F; Lo Re G; Donini M; Bortolus R; Spizzo G; D'Angelo A; Zagonel V; Procopio G; Mattioli R; Mansueto G; Facchini G; Aieta M; Scognamiglio F; Ortega C; Di Lorenzo G; Caffo O; De Giorgi U; et alii...

Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes in Journal of Clinical Oncology

2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Maines F; De Giorgi U; Facchini G; Fratino L; Gasparro D; Alesini D; Basso U; Tucci M; Ortega C; Scagliarini S; Verderame F; Barni S; D'Angelo A; Vicario G; Donini M; Carrozza F; Sava T; Sirotova Z; Santini D; Caffo O;

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study in Journal of Clinical Oncology

2016
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Alesini D; Fratino L; Ortega C; Tucci M; Scagliarini S; Zagonel V; Zucali PA; Morelli F; Sartori D; Sabbatini R; D'Angelo A; Donini M; Barni S; Procopio G; Sirotova Z; Sava T; Conteduca V; Galligioni E;

Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study in Journal of Clinical Oncology

2016
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Ferrau F; Donini M; Facchini G; Maruzzo M; Tucci M; Conteduca V; Maines F; Rossi L; Veccia A; Galligioni E;

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. in European urology / Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.

2015
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; et alii...

Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study in Journal of Clinical Oncology

2015
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Facchini G; Fratino L; Gasparro D; Basso U; Alesini D; Tucci M; Ortega C; Verderame F; Procopio G; Lo Re G; Campadelli E; Omarini C; Donini M; Morelli F; Zucali PA; Sartori D; Conteduca V; Galligioni E;

Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience in Journal of Clinical Oncology

2014
AOU San Luigi di Orbassano

Caffo O; Basso U; Facchini G; Gasparro D; Alesini D; Tucci M; Ortega C; Fratino L; Campadelli E; Lo Re G; Sabbatini R; Procopio G; Zucali PA; D'Angelo A; Donini M; Massari F; Ratta R; Sava T; Messina C; De Giorgi U;